Overview

A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy

Status:
Recruiting
Trial end date:
2022-02-09
Target enrollment:
Participant gender:
Summary
The study's main purpose is to asses the safety, tolerability, and effect of oral administration of RG7774 on the severity of diabetic retinopathy (DR) in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) and good vision.
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche